Want to see JP:4896 full AI Analyst Report?

K Pharma,Inc. (4896) Price & Analysis

0 Followers

4896 Stock Chart & Stats

¥651.00

¥14.00(2.16%)

At close: Jan 08 4:00 PM EST

¥651.00

¥14.00(2.16%)

Day’s Range― - ―

52-Week Range¥604.00 - ¥949.00

Previous CloseN/A

Volume10.50K

Average Volume (3M)48.08K

Market Cap

¥8.46B

Enterprise Value¥6.37B

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta0.88

Next Earnings

Aug 13, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-21.56

Shares Outstanding11,622,600

10 Day Avg. Volume47,520

30 Day Avg. Volume48,080

Financial Highlights & Ratios

PEG Ratio-0.44

Price to Book (P/B)6.05

Price to Sales (P/S)0.00

P/FCF Ratio-8.24

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Proven Revenue Generation (historical)The company delivered ¥1.0B revenue and ¥260M net income in 2023, demonstrating the ability to commercialize or monetize assets historically. That track record suggests the business model can generate revenue if programs or partnerships resume execution, providing a path back to profitability over months.

Improving Cash Burn TrendFree cash flow improved modestly in 2025 versus 2024, indicating management has taken steps to slow the cash burn. A sustained downward trend in negative OCF/FCF extends runway, increases optionality for partnering or non-dilutive funding, and supports near-term program continuity over the coming months.

Lean R&D-focused Structure And Asset BaseA small, 20-person organization with an R&D-focused cost profile and roughly ¥2.94B in assets implies a lean, development-stage biotech setup. This structure can preserve capital, concentrate expertise on core programs, and make the company an attractive partner or acquisition target if milestone progress is achieved.

Bears Say

Zero Revenue In Recent YearsReporting no revenue for two consecutive years removes margin visibility and undermines sustainable earnings. Without revenue, the company must rely on financing or one-off events to fund operations, increasing execution risk and lowering predictability of cash generation over the next several months.

Sustained Negative Cash Flow / Cash BurnConsistent negative operating and free cash flow near -¥0.9B annually creates a material funding gap. Persistent cash burn reduces runway, forces reliance on external capital (likely dilutive), and constrains R&D timelines and partner negotiations, posing a durable financing risk absent revenue or fresh financing.

Eroding Equity And Rising LeverageEquity erosion alongside rising debt increases leverage and reduces financial flexibility. A debt-to-equity ratio near 1.2x and materially lower equity limit ability to raise non-dilutive capital, heighten refinancing risk, and worsen credit terms, impeding the company's capacity to fund long-term development programs.

4896 FAQ

What was K Pharma,Inc.’s price range in the past 12 months?

K Pharma,Inc. lowest stock price was ¥604.00 and its highest was ¥949.00 in the past 12 months.

What is K Pharma,Inc.’s market cap?

K Pharma,Inc.’s market cap is ¥8.46B.

When is K Pharma,Inc.’s upcoming earnings report date?

K Pharma,Inc.’s upcoming earnings report date is Aug 13, 2026 which is in 9 days.

How were K Pharma,Inc.’s earnings last quarter?

K Pharma,Inc. released its earnings results on May 14, 2026. The company reported -¥21.56 earnings per share for the quarter, missing the consensus estimate of N/A by -¥21.56.

Is K Pharma,Inc. overvalued?

According to Wall Street analysts K Pharma,Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does K Pharma,Inc. pay dividends?

K Pharma,Inc. does not currently pay dividends.

What is K Pharma,Inc.’s EPS estimate?

K Pharma,Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does K Pharma,Inc. have?

K Pharma,Inc. has 11,622,600 shares outstanding.

What happened to K Pharma,Inc.’s price movement after its last earnings report?

K Pharma,Inc. reported an EPS of -¥21.56 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.499%.

Which hedge fund is a major shareholder of K Pharma,Inc.?

Currently, no hedge funds are holding shares in JP:4896

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

K Pharma,Inc.

K Pharma, Inc., headquartered in Minato, Japan, was established in 2016 and operates within the Japanese market. The company is dedicated to the research, development, production, and sale of both regenerative medicines and pharmaceutical products. A key focus within their regenerative medicine efforts involves leveraging disease-specific induced pluripotent stem (iPS) cell technology, primarily to develop treatments for conditions such as spinal cord injuries and cerebral infarctions.